Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 482 pembrolizumab 456 Magnetic Resonance Spectroscopy 419 Carboplatin 322 Cyclophosphamide 317 Biopsy 270 Cisplatin 263 Radiotherapy 238 Paclitaxel 227 Gemcitabine 222 Bevacizumab 214 Nivolumab 190 fludarabine 185 venetoclax 172 Drug Therapy 165 Blood Specimen Collection 157 Dexamethasone 156 Oxaliplatin 154 Injections 152 Capecitabine 152 Fluorouracil 144 Docetaxel 142 Standard of Care 138 Radiosurgery 136 Rituximab 125 Pemetrexed 115 durvalumab 113 atezolizumab 110 Leucovorin 110 Surveys and Questionnaires 104

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × DLL3 protein, human × 1 year × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡